Molecular Partners reports progress and milestones at J.P. Morgan Conference in San Francisco.
In a recent announcement on Jan. 11, 2026, Molecular Partners AG, a clinical-stage biotech company listed on the SIX and NASDAQ exchanges under the tickers MOLN, provided important updates on its advancements. The company specializes in DARPin therapeutics, a unique class of protein drugs. Molecular Partners, based in Zurich-Schlieren, Switzerland, and Concord, Massachusetts, shared insights on its progress, development strategies, and anticipated milestones for 2026. These updates are scheduled to be discussed at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments